308 related articles for article (PubMed ID: 8560416)
1. Mechanisms of platelet dysfunction and response to DDAVP in patients with congenital platelet function defects. A double-blind placebo-controlled trial.
Rao AK; Ghosh S; Sun L; Yang X; Disa J; Pickens P; Polansky M
Thromb Haemost; 1995 Oct; 74(4):1071-8. PubMed ID: 8560416
[TBL] [Abstract][Full Text] [Related]
2. Platelet aggregation at high shear is impaired in patients with congenital defects of platelet secretion and is corrected by DDAVP: correlation with the bleeding time.
Cattaneo M; Pareti FI; Zighetti M; Lecchi A; Lombardi R; Mannucci PM
J Lab Clin Med; 1995 Apr; 125(4):540-7. PubMed ID: 7706911
[TBL] [Abstract][Full Text] [Related]
3. Response of von Willebrand factor parameters to desmopressin in patients with type 1 and type 2 congenital von Willebrand disease: diagnostic and therapeutic implications.
Michiels JJ; van de Velde A; van Vliet HH; van der Planken M; Schroyens W; Berneman Z
Semin Thromb Hemost; 2002 Apr; 28(2):111-32. PubMed ID: 11992235
[TBL] [Abstract][Full Text] [Related]
4. [Utility of desmopressin in 4 cases of thrombocytopathies associated with giant platelets].
Martínez-Murillo C; Quintana-González S; Ambriz-Fernández R; Arzate-Hernández G; Gutiérrez-Romero M; Gaminio-Gómez E
Rev Invest Clin; 1997; 49(4):281-6. PubMed ID: 9707993
[TBL] [Abstract][Full Text] [Related]
5. Laboratory response to intranasal desmopressin in women with menorrhagia and platelet dysfunction.
Rose SS; Faiz A; Miller CH; Saidi P; Philipp CS
Haemophilia; 2008 May; 14(3):571-8. PubMed ID: 18312366
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of desmopressin effects on haemostasis in children with congenital bleeding disorders.
Hanebutt FL; Rolf N; Loesel A; Kuhlisch E; Siegert G; Knoefler R
Haemophilia; 2008 May; 14(3):524-30. PubMed ID: 18284449
[TBL] [Abstract][Full Text] [Related]
7. Subcutaneous desmopressin (DDAVP) shortens the prolonged bleeding time in patients with liver cirrhosis.
Cattaneo M; Tenconi PM; Alberca I; Garcia VV; Mannucci PM
Thromb Haemost; 1990 Nov; 64(3):358-60. PubMed ID: 2096487
[TBL] [Abstract][Full Text] [Related]
8. A point-of-care assessment of the effects of desmopressin on impaired platelet function using multiple electrode whole-blood aggregometry in patients after cardiac surgery.
Weber CF; Dietrich W; Spannagl M; Hofstetter C; Jámbor C
Anesth Analg; 2010 Mar; 110(3):702-7. PubMed ID: 20042444
[TBL] [Abstract][Full Text] [Related]
9. [Shortening of acetylsalicylic acid-prolonged bleeding time by means of desmopressin].
Beck KH; Bleckmann U; Mohr P; Kretschmer V; Huss B
Beitr Infusionsther Transfusionsmed; 1994; 32():437-9. PubMed ID: 9480140
[TBL] [Abstract][Full Text] [Related]
10. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
[TBL] [Abstract][Full Text] [Related]
11. Laboratory diagnosis and molecular classification of von Willebrand disease.
Gadisseur A; Hermans C; Berneman Z; Schroyens W; Deckmyn H; Michiels JJ
Acta Haematol; 2009; 121(2-3):71-84. PubMed ID: 19506352
[TBL] [Abstract][Full Text] [Related]
12. Study on mechanisms of a haemostatic effect of 1 deamino-8-D-arginine vasopressin (desmopressin) in uraemic patients.
Malyszko J; Pietraszek M; Buczko W; Mysliwiec M
Folia Haematol Int Mag Klin Morphol Blutforsch; 1990; 117(2):319-24. PubMed ID: 1697836
[TBL] [Abstract][Full Text] [Related]
13. Post-DDAVP thrombocytopenia in type 2B von Willebrand disease is not associated with platelet consumption: failure to demonstrate glycocalicin increase or platelet activation.
Casonato A; Steffan A; Pontara E; Zucchetto A; Rossi C; De Marco L; Girolami A
Thromb Haemost; 1999 Feb; 81(2):224-8. PubMed ID: 10063996
[TBL] [Abstract][Full Text] [Related]
14. Characterization, classification, and treatment of von Willebrand diseases: a critical appraisal of the literature and personal experiences.
Michiels JJ; Gadisseur A; Budde U; Berneman Z; van der Planken M; Schroyens W; van de Velde A; van Vliet H
Semin Thromb Hemost; 2005 Nov; 31(5):577-601. PubMed ID: 16276467
[TBL] [Abstract][Full Text] [Related]
15. 1-Desamino-8-D-arginine vasopressin (DDAVP) in patients with congenital nephrogenic diabetes insipidus.
Brink HS; Derkx FH; Boomsma F; Brommer EJ; Schalekamp MA
Neth J Med; 1993 Aug; 43(1-2):5-12. PubMed ID: 8232694
[TBL] [Abstract][Full Text] [Related]
16. Uremic plasma after infusion of desmopressin (DDAVP) improves the interaction of normal platelets with vessel subendothelium.
Escolar G; Cases A; Monteagudo J; Garrido M; Lopez J; Ordinas A; Revert L; Castillo R
J Lab Clin Med; 1989 Jul; 114(1):36-42. PubMed ID: 2738447
[TBL] [Abstract][Full Text] [Related]
17. Shortening of bleeding time by 1-deamino-8-arginine vasopressin (DDAVP) in the absence of platelet von Willebrand factor in Gray platelet syndrome.
Pfueller SL; Howard MA; White JG; Menon C; Berry EW
Thromb Haemost; 1987 Dec; 58(4):1060-3. PubMed ID: 3502198
[TBL] [Abstract][Full Text] [Related]
18. Desmopressin (DDAVP) in bleeding disorders of childhood.
Sutor AH
Semin Thromb Hemost; 1998; 24(6):555-66. PubMed ID: 10066151
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of desmopressin effect on primary haemostasis in pediatric patients with aspirin-like defect as hereditary thrombocytopathy.
Tauer JT; Gneuss A; Lohse JE; Jürgens T; Knöfler R
Klin Padiatr; 2011 May; 223(3):169-72. PubMed ID: 21509710
[TBL] [Abstract][Full Text] [Related]
20. Recessive von Willebrand disease type 2 Normandy: variable expression of mild hemophilia and VWD type 1.
Michiels JJ; Gadisseur A; Vangenegten I; Schroyens W; Berneman Z
Acta Haematol; 2009; 121(2-3):119-27. PubMed ID: 19506358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
